Experimental Tardive Dyskinesia Drug Hits Mark in Phase 3Experimental Tardive Dyskinesia Drug Hits Mark in Phase 3

Neurocrine Biosciences' drug NBI-98854 eases symptoms of tardive dyskinesia in a phase 3 study. Medscape Medical News
Source: Medscape Psychiatry Headlines - Category: Psychiatry Tags: Psychiatry News Source Type: news